本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
内容审核：方程
项目审核：于轩
题图来源：图虫创意
[1]赵媛媛, 周建英, 范云, 等. BRAF V600 突变型非小细胞肺癌的治疗进展 [J]. 中国癌症杂志, 2021, 31(12): 1145-1152.
[2]Mu YX, Yang K, Hao XZ, et al. Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated nonsmall cell lung cancer［J］. Front Oncol, 2020, 10: 603.
[3]Couraud S, Barlesi F, Fontaine-Deraluelle C, et al. Clinical outcomes of non-small cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study［J］. Eur J Cancer, 2019, 116: 86-97.
[4]Dudnik E, Peled N, Nechushtan H, et al. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors[J]. J Thorac Oncol. 2018 Aug;13(8):1128-1137.
[5]Guisier F, Dubos-Arvis, Vinas F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018［J］. J Thorac Oncol, 2020, 15(4): 628-636.
[6]Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry［J］. Ann Oncol, 2019, 30(8): 1321-1328.
[7]中国晚期非小细胞肺癌 BRAF 突变诊疗专家共识.
[8]中国医师协会肿瘤多学科诊疗专业委员会，国家肿瘤质控中心肺癌质控专家委员会. 原发性肺癌罕见靶点靶向治疗中国临床诊疗指南（2024 版）[J]. 中国肿瘤临床与康复，2024，31（5）：265-295.
[9]Planchard D,et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Lancet Oncol. 2017;18(10):1307-1316.
[10]Fan Yun, et al. Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic NSCLC2022 WCLC EP08.02-52
[11]Wiesweg M, et al. Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy. 2024 ESMO 1300P.
[12]Russo A, et al. BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database. 2024 ESMO 1301P.
